Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A proposed modification to the Best Pharmaceuticals for Children Act to benefit pediatric oncology.

Needle MN.

Pediatr Blood Cancer. 2012 Jul 15;59(1):3-4. doi: 10.1002/pbc.24115. Epub 2012 Feb 29. No abstract available.

PMID:
22378597
2.

Pharmaceuticals: pharmaceutical assistance programs: year end report-2002.

Kammer C.

Issue Brief Health Policy Track Serv. 2002 Dec 31:1-18. No abstract available.

PMID:
12856688
3.

Covering kids: states are working to provide public health insurance to the growing number of eligible children.

Breshears J, Foreman M.

State Legis. 2009 Jun;35(6):28-30. No abstract available.

PMID:
19492502
4.

Will children with cancer benefit from the new European Paediatric Medicines Regulation?

Vassal G.

Eur J Cancer. 2009 Jun;45(9):1535-46. doi: 10.1016/j.ejca.2009.04.008. Epub 2009 May 4.

PMID:
19419857
5.

Pharmaceuticals: state pharmaceutical assistance programs (SPAPs).

Hilyard K, Seay M, Howe WC.

Issue Brief Health Policy Track Serv. 2007 Jan 8:1-20. No abstract available.

PMID:
17361469
6.

Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.

Seay M.

Issue Brief Health Policy Track Serv. 2004 Dec 31:1-26. No abstract available.

PMID:
15724309
7.

Stimulation programs for pediatric drug research--do children really benefit?

Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, Burggraaf J.

Eur J Pediatr. 2007 Aug;166(8):849-55. Epub 2007 Jan 17.

8.

Utilization of Unused Prescriptions Medication Act.

Broyles M, Broyles VP, Meritt Y.

J Okla State Med Assoc. 2007 Mar;100(3):82-4.

PMID:
17432034
9.

The EU's new paediatric medicines legislation: serving children's needs?

Permanand G, Mossialos E, McKee M.

Arch Dis Child. 2007 Sep;92(9):808-11. Review.

10.

Specializing in pediatric hematology and oncology.

Beavers MB.

Am J Health Syst Pharm. 2007 Apr 15;64(8):812-3. No abstract available.

PMID:
17420194
11.

[The child and cancerous diseases (current general aspects of pediatric oncology)].

Goldiş G.

Rev Pediatr Obstet Ginecol Pediatr. 1982 Jan-Mar;31(1):3-14. Review. Romanian. No abstract available.

PMID:
6808641
12.

[Place of CSF in pediatric oncology].

Hartmann O, Valteau-Couanet D.

Pathol Biol (Paris). 1993 Jan;41(1):52. French. No abstract available.

PMID:
7686289
14.

Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.

Chaps NA.

Issue Brief Health Policy Track Serv. 2010 Jan 4:1-18. No abstract available.

PMID:
20213921
15.
16.

The European paediatric initiative: 1 year of experience.

Saint-Raymond A, Seigneuret N.

Paediatr Drugs. 2009;11(1):9-10.

PMID:
19127942
17.

Complementary and alternative therapy use in pediatric oncology patients with failure of frontline chemotherapy.

Paisley MA, Kang TI, Insogna IG, Rheingold SR.

Pediatr Blood Cancer. 2011 Jul 1;56(7):1088-91. doi: 10.1002/pbc.22939. Epub 2011 Feb 25.

PMID:
21360653
18.

[Present and future of therapeutic oncology].

García G, Beltrán-Ortega A, Díaz-Perches R, de la Garza-Salazar JG, Noriega-Limón J, Jiménez-Zamudio L.

Gac Med Mex. 1984 Jul-Aug;120(7-8):281-300. Spanish. No abstract available.

PMID:
6526215
19.

The state Children's Health Insurance Program (CHIP).

Jenkins J, Faulkner T.

J Am Acad Nurse Pract. 2002 Oct;14(10):438-42. Review.

PMID:
12426800
20.

Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.

Health Policy Tracking Service, A Service of Thomson Reuters/West.

Issue Brief Health Policy Track Serv. 2011 Jan 3:1-21. No abstract available.

PMID:
21374837

Supplemental Content

Support Center